肌钙蛋白引导的冠状动脉CTA在排除心肌梗死后识别隐匿性冠心病
本研究为前瞻性队列研究,纳入250例疑似急性冠脉综合征且高敏肌钙蛋白I低于性别特异性第99百分位的患者,所有患者出院后行冠状动脉CTA。结果发现中间浓度组(5 ng/L至第99百分位)的冠心病风险是低浓度组(<5 ng/L)的3倍,且心绞痛症状与冠心病无关。多数冠心病患者既往未诊断且未接受抗血小板和他汀治疗。
要点
- 排除心梗后,hs-cTnI在5 ng/L至99百分位者冠心病风险是<5 ng/L者的3.33倍。
- 心绞痛症状与冠心病无显著关联(OR 0.92,95%CI 0.48-1.76)。
- 多数冠心病患者既往未诊断且未用抗血小板/他汀,CCTA可识别隐匿性冠心病。
核心结论
- 在排除心肌梗死的患者中,中间浓度hs-cTnI者冠心病可能性是低浓度者的3倍,CCTA有助于识别隐匿性冠心病并指导预防治疗。
研究设计与样本
- 前瞻性队列研究,纳入250例疑似急性冠脉综合征且hs-cTnI低于性别特异性第99百分位的急诊患者,按峰值hs-cTnI以2:1比例分层(高于和低于5 ng/L),出院后行CCTA。
主要发现
- 250例患者中62.4%(156/250)患有冠心病。
- 中间hs-cTnI浓度组冠心病比例为71.9%(120/167),低浓度组为43.4%(36/83),OR 3.33(95%CI 1.92-5.78)。
- 心绞痛症状与冠心病无关:有症状组63.2%(67/106)vs 无症状组61.8%(89/144),OR 0.92(95%CI 0.48-1.76)。
- 53.2%(83/156)的冠心病患者既往未诊断,63.5%(99/156)未接受抗血小板和他汀治疗。
关键数值与推荐
- hs-cTnI风险分层阈值为5 ng/L,低于性别特异性第99百分位为纳入标准。
- 中间浓度定义为5 ng/L至性别特异性第99百分位之间。
临床怎么用
- 对疑似急性冠脉综合征且排除心梗、hs-cTnI处于中间浓度的患者,可考虑CCTA以识别隐匿性冠心病并启动预防治疗。
局限性
- 样本量250例,单中心前瞻性队列,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with suspected acute coronary syndrome in whom myocardial infarction has been excluded are at risk of future adverse cardiac events. OBJECTIVES: This study evaluated the usefulness of high-sensitivity cardiac troponin I (hs-cTnI) to select patients for further investigation after myocardial infarction has been excluded. METHODS: This is a prospective cohort study of patients presenting to the emergency department with suspected acute coronary syndrome and hs-cTnI concentrations below the sex-specific 99th percentile. Patients were recruited in a 2:1 fashion, stratified by peak hs-cTnI concentration above and below the risk stratification threshold of 5 ng/L. All patients underwent coronary computed tomography angiography (CCTA) after hospital discharge. RESULTS: Overall, 250 patients were recruited (61.4 ± 12.2 years 31% women) in whom 62.4% (156 of 250 patients) had coronary artery disease (CAD). Patients with intermediate hs-cTnI concentrations (between 5 ng/L and the sex-specific 99th percentile) were more likely to have CAD than those with hs-cTnI concentrations <5 ng/L (71.9% [120 of 167 patients] vs 43.4% [36 of 83 patients]; odds ratio: 3.33; 95% CI: 1.92-5.78). Conversely, there was no association between anginal symptoms and CAD (63.2% [67 of 106 patients] vs 61.8% [89 of 144 patients]; odds ratio: 0.92; 95% CI: 0.48-1.76). Most patients with CAD did not have a previous diagnosis (53.2%; 83 of 156 patients) and were not on antiplatelet and statin therapies (63.5%; 99 of 156 patients) before they underwent CCTA. CONCLUSIONS: In patients who had myocardial infarction excluded, CAD was 3× more likely in those with intermediate hs-cTnI concentrations compared with low hs-cTnI concentrations. In such patients, CCTA could help to identify those with occult CAD and to target preventative treatments, thereby improving clinical outcomes.
引用
- Lee KK, Bularga A, O'Brien R, et al. Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction. J Am Coll Cardiol. 2021. PMID: 34593122. doi:10.1016/j.jacc.2021.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。